Aptose Biosciences (APTO) - חוב לטווח ארוך להון

Aptose Biosciences Inc. (APTO) attracts leading oncologists by developing drugs that inhibit the division of leukemic cells, sustaining its staff through R&D budgets. This chart on the GURU.Markets platform reflects the asset's dynamics, with a value of 0.00. Aptose Biosciences Inc. (APTO) develops high-precision small molecules to target genetic defects in tumors. The current strategic direction relies on finding strategic partners to fund clinical trials.

This indicator measures the proportion of liabilities with a maturity of over one year relative to the issuer's equity. An increase in this metric signals rising leverage and the potential risk of higher debt service costs. By analyzing the long-term debt-to-equity structure, an investor assesses the sustainability of the financial model. For Aptose Biosciences Inc. (APTO), this is critical when financing the development of kinase inhibitors. High demand for leukemia therapies requires a balance between borrowed capital and operational flexibility.